Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Sangamo Therapeutics Inc (NASDAQ: SGMO) closed the day trading at $0.47 up 4.44% from the previous closing price of $0.45. In other words, the price has increased by $4.44 from its previous closing price. On the day, 5.81 million shares were traded.
Ratios:
For a better understanding of SGMO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 0.76. In the meantime, Its Debt-to-Equity ratio is 5.07 whereas as Long-Term Debt/Eq ratio is at 5.07.
On December 10, 2024, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $10.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 03, 2023, whereas the target price for the stock was revised from $6 to $2.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.81 while its Price-to-Book (P/B) ratio in mrq is 21.59.
Stock Price History:
Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.30. The 50-Day Moving Average of the stock is -37.56%, while the 200-Day Moving Average is calculated to be -60.82%.
Shares Statistics:
A total of 245.40M shares are outstanding, with a floating share count of 234.62M. Insiders hold about 4.39% of the company’s shares, while institutions hold 21.55% stake in the company.
Earnings Estimates
A detailed examination of Sangamo Therapeutics Inc (SGMO) is currently in progress, with 3.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.1 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.39 and -$0.54 for the fiscal current year, implying an average EPS of -$0.46. EPS for the following year is -$0.4, with 3.0 analysts recommending between -$0.35 and -$0.46.
Revenue Estimates
6 analysts predict $29.9M in revenue for the current quarter. It ranges from a high estimate of $100M to a low estimate of $400k. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $356k
A total of 7 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $106.4M, while the lowest revenue estimate was $20.8M, resulting in an average revenue estimate of $48.74M. In the same quarter a year ago, actual revenue was $57.8MBased on 7 analysts’ estimates, the company’s revenue will be $42.57M in the next fiscal year. The high estimate is $114.2M and the low estimate is $9.9M.
